This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
by Ahan Chakraborty
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
LLYPositive Net Change MRKPositive Net Change GILDPositive Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
by Ekta Bagri
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
GILDPositive Net Change GSKPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
by Zacks Equity Research
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
LLYPositive Net Change SNYNegative Net Change BMYPositive Net Change
biotechs medical pharmaceuticals
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
by Sundeep Ganoria
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
TEVANegative Net Change ALPMYPositive Net Change CSLLYPositive Net Change BBIONegative Net Change UCBJYPositive Net Change ONCPositive Net Change
biotechs medical pharmaceuticals
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
by Zacks Equity Research
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
AXSMNegative Net Change JAZZPositive Net Change RGENNegative Net Change ANIKNegative Net Change
biotechs
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
by Ahan Chakraborty
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
ALNYNegative Net Change BMRNNegative Net Change RARENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
by Sundeep Ganoria
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
NBIXPositive Net Change VRTXPositive Net Change CRNXNo Net Change
biotechs medical pharmaceuticals
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
by Ekta Bagri
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
LQDANegative Net Change UTHRNegative Net Change INSMPositive Net Change
biotechnology biotechs medical pharmaceuticals
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
by Zacks Equity Research
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
LLYPositive Net Change NVOPositive Net Change ALDXNegative Net Change ACIUPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
by Ahan Chakraborty
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals